Eric Kauderer-Abrams leads life sciences at Anthropic. He is one of the six listed authors of the September 23, 2026 preprint reporting array-associated reverse transcriptases (Autonomous AI agents discover reverse transcriptases with tandem repeat arrays (Yoon et al., Anthropic, September 2026)), the first published result of the company's life sciences research group.
Role at Anthropic
Kauderer-Abrams confirmed Anthropic's San Francisco Bay Area biology laboratory in an interview of September 15, 2026, saying "we believe that to do biology, the final test is still and will be for a while in real lab work," and describing a mix of in-house facilities and external partners typical of biotechnology companies. He stated in the same interview that the company is not running clinical trials for the time being, partly over competition concerns: "We're not competing with pharma and biotech companies that make their business in bringing drugs to market" (Source: reuters.com).
Anthropic's announcement of the ART result describes the group as scientists who specialize in computational approaches to reading DNA and selecting biological systems for characterization, and places it within the company's wider life sciences organization alongside teams working on drug discovery and on training Claude in biology and chemistry (Source: anthropic.com). Coverage and company statements to date give no further biographical detail about him, and the preprint lists him only by affiliation.
Relationships
- related: Anthropic — employer.
- related: Autonomous AI agents discover reverse transcriptases with tandem repeat arrays (Yoon et al., Anthropic, September 2026) — co-author.
- related: AI for Science — the research programme he leads.